These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37153730)

  • 1. Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy.
    Reddy SK; Ballal AR; Shailaja S; Seetharam RN; Raghu CH; Sankhe R; Pai K; Tender T; Mathew M; Aroor A; Shetty AK; Adiga S; Devi V; Muttigi MS; Upadhya D
    Theranostics; 2023; 13(7):2241-2255. PubMed ID: 37153730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
    Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
    Yang CS; Hung KC; Huang YM; Hsu WM
    J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.
    Zehden JA; Mortensen XM; Reddy A; Zhang AY
    Curr Diab Rep; 2022 Oct; 22(10):525-536. PubMed ID: 36053385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
    Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D
    Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats.
    Ma J; Zhu T; Tang X; Ye P; Zhang Z
    Clin Exp Ophthalmol; 2010 Dec; 38(9):875-84. PubMed ID: 20653693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
    Nicholson BP; Schachat AP
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
    Spaide RF; Fisher YL
    Retina; 2006 Mar; 26(3):275-8. PubMed ID: 16508426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
    di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage.
    Lv J; Chen MM; Mu ZH; Wang F; Qian ZY; Zhou L; Guo QT; Zhao ZM; Pan YP; Liao XY; Yang ZH; Cai N; Li SD; Zou YY
    J Diabetes Res; 2018; 2018():9216791. PubMed ID: 29977927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
    Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
    Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
    Simunovic MP; Maberley DA
    Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.
    Tan Y; Fukutomi A; Sun MT; Durkin S; Gilhotra J; Chan WO
    Surv Ophthalmol; 2021; 66(6):926-932. PubMed ID: 33705807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
    Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
    Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
    Higashide T; Murotani E; Saito Y; Ohkubo S; Sugiyama K
    Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):603-10. PubMed ID: 22116499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.